OBJECTIVE In the present study, we employ mathematical modeling (partial least squares regression, PLSR) to elucidate the functional connectivity signatures of discrete brain regions in order to identify the functional networks subserving PCP-induced disruption of distinct cognitive functions and their restoration by the procognitive drug modafinil. METHODS We examine the functional connectiv...

Modafinil is a wakeness-promoting drug, which is effective in the treatment of narcolepsy; its effects on learning processes are however little studied. Thus, the present study was aimed at determining the effects of an acute modafinil injection on a serial reversal discrimination task performed in a T-maze in mice. Independent groups of mice varying by the level of pretest training (either 1 o...

Excessive daytime sleepiness is a frequent and a highly disruptive symptom to the daily routine of children with Prader-Willi Syndrome (PWS) and their families. The objective of the study was to evaluate the efficacy of modafinil, a central stimulant, on excessive daytime sleepiness in children and adolescents with PWS. The efficacy of modafinil was evaluated in this open label pilot study comp...

Modafinil (Provigil) is a medication used to promote wakefulness. Originally marketed in 1998, modafinil, a Schedule C-IV drug, was approved by the Food and Drug Administration (FDA) for the treatment of excessive sleepiness (ES) associated with narcolepsy. In 2003, the FDA approved modafinil for the treatment of ES associated with obstructive sleep apnea-hypopnea syndrome (only as an adjunct t...

13. Ripley B, Overeem S, Fujiki N, Nevsimalova S, Uchino M, Yesavage J, et al. CSF hypocretin/orexin levels in narcolepsy and other neurological conditions. Neurology 2001;57:2253-8. 14. Honda Y. Clinical features of narcolepsy: Japanese experiences. In: Honda Y, Juji T, editors. HLA in narcolepsy. Berlin: Springer-Verlag; 1988. p. 24-57. 15. US Modafinil in Narcolepsy Multicenter Study Group. ...

BACKGROUND AND PURPOSE This study aimed to assess the efficacy of modafinil, a wakefulness-promoting agent in alleviating post-stroke fatigue ≥3 months after stroke. We hypothesized that 200 mg of modafinil daily for 6 weeks would result in reduced symptoms of fatigue compared with placebo. METHODS This single-center phase 2 trial used a randomized, double-blind, placebo-controlled, crossover...

BACKGROUND Modafinil is employed for the treatment of narcolepsy and has also been, off-label, used to treat cognitive dysfunction in neuropsychiatric disorders. In a previous study, we have reported that single dose administration of modafinil in healthy young subjects enhances fluid reasoning and affects resting state activity in the Fronto Parietal Control (FPC) and Dorsal Attention (DAN) ne...

In the past few years, cognitive enhancing drugs (CEDs) have gained growing interest and the focus of investigations aimed at exploring their use to potentiate the cognitive performances of healthy individuals. Most of this exploratory CED-related research has been performed on young adults. However, CEDs may also help to maintain optimal brain functioning or compensate for subtle and or subcli...

two simple visible spectrophotometric methods are developed and validated for the quantification of modafinil using 1,2-naphthoquinone-4-sulphonic acid (nqs method) and 2,4-dinitrophenol (dnp method) as analytical reagents. the nqs method involves the reaction of modafinil with 1,2-naphthoquinone-4-sulphonate in alkaline medium at room conditions to form a yellow colored product exhibiting maxi...

Atypical depression, with features of hypersomnia, hyperphagia, anergia, and rejection sensitivity, is a common presentation of major depressive disorder. There are few available effective therapies for this disorder. We test modafinil, a novel wake-promoting agent, as monotherapy for atypical depression in a double-blind, placebo-controlled, relapse prevention trial after open-label treatment....